LON:DXRX

Diaceutics (DXRX) Share Forecast, Price & News

GBX 111.90

+1.40 (+1.27%)

(As of 05/27/2022 11:09 AM ET)

Add

Compare

Today's Range: 111.90
▼
112
50-Day Range: 98
▼
122
52-Week Range: 97
▼
130

Volume: 6,186 shs
Average Volume: 54,281 shs
Market Capitalization: £94.33 million

P/E Ratio: 159.86
Dividend Yield: N/A
Beta: N/A

30 days | 90 days | 365 days | Advanced Chart

Receive DXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter.

About Diaceutics

Diaceutics PLC provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories, which provides lab mapping, testing dashboard, and physician mapping services. The company also provides DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics in a secure and standardized way. In addition, it offers diagnostic landscape, planning, implementation, and tracking services; and consulting services for precision medicine diagnostics. Further, the company provides test standardization, test quality assessment, test report optimization, laboratory tech support, test access and reimbursement, laboratory training, and educational resources services. Diaceutics PLC was incorporated in 2005 and is based in Belfast, the United Kingdom.

May 23, 2022 | finance.yahoo.com

Diaceutics PLC (LON:DXRX) Has Varied Financials: Could That Be Why Its Recent Performance Has Been Uneventful?

May 5, 2022 | lse.co.uk

Diaceutics inks five-year deal with existing pharma partner

April 7, 2022 | finance.yahoo.com

The past year for Diaceutics (LON:DXRX) investors has not been profitable

March 22, 2022 | lse.co.uk

Diaceutics returns to pretax profit in 2021 and ups revenue

March 16, 2022 | marketwatch.com

Diaceutics Approved by US Agency to Receive Enhanced Data

February 14, 2022 | marketwatch.com

Diaceutics Gets Three-Year Contract Worth More Than $2.5 Mln

January 11, 2022 | lse.co.uk

Diaceutics hails DXRX platform for strong annual sales and earnings

January 11, 2022 | marketwatch.com

Diaceutics Appoints Nick Roberts CFO, 2021 Revenue rose 10%

December 15, 2021 | finance.yahoo.com

Is Diaceutics PLC (LON:DXRX) Trading At A 50% Discount?

November 9, 2021 | finance.yahoo.com

Global Personalized Medicine Market grow at 6.2% : Qualiket Research

September 10, 2021 | finance.yahoo.com

Diaceutics Announces Two Poster Presentations at AMP 2021 Annual Meeting & Expo

September 8, 2021 | finance.yahoo.com

Two New Experts Join the Diaceutics Advisory Panel

September 3, 2021 | finance.yahoo.com

Shareholders in Diaceutics (LON:DXRX) are in the red if they invested a year ago

See More Headlines

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Pharmaceuticals: Other
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:DXRX
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: www.diaceutics.com
Phone: N/A
Fax: N/A
Employees: 133
Year Founded: N/A

Sales & Book Value

Annual Sales: £13.94 million
Price / Sales: 6.77
Cash Flow: GBX 23.48 per share
Price / Cash Flow: 4.77
Book Value: GBX 48.40 per share
Price / Book: 2.31

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 3.84
Current Ratio: 11.41
Quick Ratio: 11.24

Price-To-Earnings

Trailing P/E Ratio: 159.86
Forward P/E Ratio: 27.49
P/E Growth: N/A

Miscellaneous

Outstanding Shares: 84,302,000
Free Float: N/A
Market Cap: £94.33 million
Optionable: Not Optionable

MarketRank^™

Overall MarketRank^™

1.21 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Diaceutics.

4.4 Community Rank

Outperform Votes
Diaceutics has received 4 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Diaceutics has received 2 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Diaceutics has received 66.67% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Diaceutics and other stocks. Vote “Outperform” if you believe DXRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DXRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Diaceutics does not currently pay a dividend.
Dividend Growth
Diaceutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Diaceutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought £5,100 in company stock and sold GBX 0 in company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Diaceutics is 159.86, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 10.00.
Price to Earnings Ratio vs. Sector
The P/E ratio of Diaceutics is 159.86, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 13.22.
Price to Book Value per Share Ratio
Diaceutics has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Diaceutics (LON:DXRX) Frequently Asked Questions

Who are Diaceutics' key executives?: Diaceutics' management team includes the following people:
Mr. Peter Keeling, Founder, CEO & Exec. Director (Age 60, Pay $273.3k)
Mr. Ryan Keeling, Chief Innovation Officer & Exec. Director (Age 39, Pay $225.32k)
Mr. Philip H. White F.C.A., Exec. Officer (Age 46, Pay $223.12k)
Mr. Nicholas Stewart Roberts, CFO & Director (Age 39)
Ms. Julie Browne, Chief Operating Officer
Ms. Zarina Bibi, VP & Gen. Counsel
Ms. Jillian Beggs, VP of Sales & Marketing
Ms. Norma Thompson, Global Head of HR
Mr. Jordan Clark, Chief Commercial Officer
Ms. Susanne Munksted, Chief Precision Officer
Who are some of Diaceutics' key competitors?: Some companies that are related to Diaceutics include Blackmores (BLMMF), Daiichi Sankyo (DSNKY), Dechra Pharmaceuticals (DCHPF), ePlus (PLUS), Medipharm Labs (MLCPF), Ono Pharmaceutical (OPHLY), OTCMKTS:WDEXF (WDEXF), Otsuka (OTSKF), Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (RGEDF), Siegfried (SGFEF), Virbac (VRBCF) and Yuhan (YUHNF).
View all of DXRX's competitors.
What is Diaceutics' stock symbol?: Diaceutics trades on the London Stock Exchange (LON) under the ticker symbol "DXRX."
How do I buy shares of Diaceutics?: Shares of DXRX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Diaceutics' stock price today?: One share of DXRX stock can currently be purchased for approximately GBX 111.90.
How much money does Diaceutics make?: Diaceutics has a market capitalization of £94.33 million and generates £13.94 million in revenue each year.
How many employees does Diaceutics have?: Diaceutics employs 133 workers across the globe.
What is Diaceutics' official website?: The official website for Diaceutics is www.diaceutics.com.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.